The suggestion that metronidazole is inactivated by the vaginal bacterial flora is supported only by experiments in which the drug was exposed to large numbers of organisms in laboratory culture.
The evidence that other protozoal pathogens, such as those causing malaria and sleeping sickness, can readily evolve populations resistant to therapeutic drugs suggested that the protozoon T vaginalis could do so also. Of some 35 papers published, however, at least 12 discounted this as the cause, one as recently as 1982.5 It is now, however, indisputable that Tvaginalis stocks resistant to metronidazole do occur and that they are a main reason for "treatment failure".
The sensitivity of T vaginalis to metronidazole can be estimated in vitro but, although the experiments reported are all of generally similar design, they differ greatly in detail. Inocula are sometimes undefined or are standardised in different ways, sometimes in terms of the volume of the culture medium, sometimes in terms of the numbers of organisms inoculated; test media are diverse in constitution, particularly regarding the content of redox agents; often the constitution of the atmosphere superjacent to the cultures is not mentioned; or anaerobic or indefinitely defined aerobic cultures are used. Progress has been made recently in controlling the oxygenation of a test medium free of redox agent, to find a level of oxygen tension at which the best compromise could be reached between good growth conditions for the organisms and measuring their susceptibility to the drug.' Using atmospheres of pure nitrogen and of a mixture of 99% nitrogen and 1% oxygen, and setting up tests from pre-titrated cryopreserved stabilates of organisms, three categories of resistance were distinguished. Organisms isolated from "random" patients were all very sensitive. Organisms from patients who were not cured by several courses ofenhanced dosages 217 218 were clearly resistant in both atmospheres. Organisms from patients who were cured by enhanced dosage were intermediate in sensitivity. Although occasional discordant results occurred, and the sample studied was small, the method offered the possibility of distinguishing "treatment-failure" patients whose infections are likely to be eliminated by enhanced dosage from those that are not.
The 5-nitroimidazoles are active against anaerobic organisms. Most of the clinically important anaerobic bacteria, such as Bacteroides spp, Fusobacterium spp, Clostridium spp bearing spores, and the protozoa susceptible to metronidazole, are inhibited by concentrations of about 3 mg/l, and anerobic Gram positive cocci and non-sporing bacilli are inhibited by about 6 mg/l.7 The action of the 5-nitroimidazoles on anaerobic organisms is believed to be in four successive steps: the entry of the drug into the organism; the activation ofthe drug by its being reduced to cytotoxic intermediates, a process that is inhibited by oxygen; the toxic effect of these short lived intermediates, killing the organism; and the release of biologically inactive end products. 8 The main thrust of this hypothesis is that the nitro group has to be reduced in the target cell to form the toxic derivative; it is ineffective without such reduction. Thus the striking feature of metronidazole's activity against anaerobic organisms, both prokaryote and eukaryote, is its reduction, which is achieved by mechanisms that are important in the metabolism of anaerobes but have only a minor role for aerobic organisms.
Uptake of metronidazole in both aerobic and anaerobic organisms appears to be passive, simply by diffusion. In aerobic organisms the intracellular and extracellular concentrations of the drug equilibrate because the drug is not metabolised, and uptake is halted. In anaerobic organisms, on the other hand, it is metabolised; its intracellular concentration is thereby decreased, so promoting its continuous uptake and the intracellular accumulation of its derivatives.
Trichomonads are peculiar in possessing membrane bound organelles, called hydrogenosomes, in their cytoplasm. These are of unknown origin and perhaps evolved from clostridia. All the enzymes responsible for the conversion of pyruvate into acetate, carbon dioxide, and also hydrogen (hence their name), via acetyl coenzyme A, appear to be located in these bodies, which also carry out the reductive activation of the 5-nitroimidazoles using electrons produced in this enzyme pathway. The electron donors are thought to be electron transport proteins of low redox potential (doxins 
